Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compendia Bioscience has licensed Oncomine, the company's compendium of oncology gene expression profiles and analysis tools, to AstraZeneca, which will conduct a year-long pilot to evaluate the long-term role of this product in its cancer research programs.
Subscribe to our email newsletter
This licensing agreement gives AstraZeneca access to Oncomine Concepts Edition (OCM), a value-added product extension of Oncomine that combines nearly 7,000 proprietary cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources.
The Concepts Map application uses gene sets as a common language to compare and link disparate biological concepts, allowing researchers to discover and explore new biology based on signatures related to drugs and disease pathways.
Jeff Hanke, vice president, cancer discovery at AstraZeneca, said: “The novel Concepts Map application may allow us to leverage traditional gene expression data in innovative new ways.”